Company OverviewCoronary Artery DiseaseTechnical ResourcesEmployment OpportunitiesWhat's New

Percardia C.E.O. Finalist for Prestigious Award

Merrimack, NH, May 15, 2003 - Percardia Inc., a venture-backed, mid-stage medical device company developing new and novel therapies for the treatment of coronary artery disease, announced today that its C.E.O., Ms. Nancy Briefs, has been named a finalist in the Ernst & Young 2003 New England Entrepreneur Of The Year® Awards Program. The award is considered the pre-eminent program for honoring outstanding business leaders of entrepreneurial companies in New England. Past recipients include leaders from some of the most recognized companies in the world such as EMC, Genzyme and Reebok Corporations.

Commenting on becoming a finalist Ms. Briefs stated, "I am honored that we have been nominated for such a prestigious award. Just the fact that our team is being recognized for its achievements in a group of other outstanding companies is really flattering". An independent panel of judges will select award recipients and the winners will be announced at the 17th Annual Entrepreneur Of The Year® Awards Banquet on Thursday, June 26, 2003 at the Boston Park Plaza Hotel. For more information about the awards program please visit the website

Percardia Inc. was founded in 1998 and has raised $42 million to date and employs 28 people. The company is currently developing the VSTENT™, a cardiovascular device implant designed to treat patients with coronary heart disease. This novel approach could address a $1.5 billion market. It's anticipated that the company's technology will require PMA Class III approval for commercialization in the USA and CE Mark for Europe.

Additional information regarding the Company and its technology can be obtained at the company's website


Press Releases | Events

Company | Coronary Artery Disease | Resources | Employment | What's New

Percardia Inc.
Heron Cove Office Park
10 Al Paul Lane, Suite 202
Merrimack, NH 03054
© 2001 Percardia Inc.